Genetic modification of hematopoietic stem cells with nonviral systems: Past progress and future prospects

Gene Therapy

Volumn 12, Issue , 2005, Pages S118-S130

  Papapetrou, E P ^a,b   Zoumbos, N C ^b   Athanassiadou, A ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Electroporation; Episomes; Gene transfer; Hematopoietic stem cells; Nonviral vectors

Indexed keywords

CATION; DNA; LIPID; MULTIDRUG RESISTANCE PROTEIN 1; PLASMID DNA; POLYMER; RETROVIRUS VECTOR;

ARTIFICIAL CHROMOSOME; BIOSAFETY; BIOTECHNOLOGY; CELL CYCLE; CELL NUCLEUS MEMBRANE; CONFERENCE PAPER; DNA MODIFICATION; ELECTROPORATION; EPISOME; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HYPERSENSITIVITY; IMMUNOGENICITY; MATERIALS HANDLING; MUTAGENESIS; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CHROMOSOMES, ARTIFICIAL, MAMMALIAN; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; PLASMIDS; TRANSCRIPTION, GENETIC;

EID: 27544501923     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302626     Document Type: Article

References (193)

1. Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259-1267.
2. Van Tendeloo VF, Van Broeckhoven C, Berneman ZN. Gene therapy: principles and applications to hematopoietic cells. Leukemia 2001; 15: 523-544.
3. Orkin SH. Diversification of hematopoietic stem cells to specific lineages. Nat Rev Genet 2000; 1: 57-64.
4. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol 2001; 17: 387-403.
5. Bordignon C et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270: 470-475.
6. Brenner MK. Gene transfer and the treatment of haematological malignancy. J Intern Med 2001; 249: 345-358.
7. Kohn DB. Gene therapy for genetic haematological disorders and immunodeficiencies. J Intern Med 2001; 249: 379-390.
8. Martin-Rendon E, Watt SM. Stem cell plasticity. Br J Haematol 2003; 122: 877-891.
9. Klein C, Baum C. Gene therapy for inherited disorders of haematopoietic cells. Hematol J 2004; 5: 103-111.
10. Bordignon C, Roncarolo MG. Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol 2002; 3: 318-321.
11. Kohn DB et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8: 180-187.
12. Recillas-Targa F, Valadez-Graham V, Farrell CM. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. BioEssays 2004; 26: 796-807.
13. Hawley RG. Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther 2001; 1: 1-17.
14. Baum C et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
15. Haviernik P, Bunting KD. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr Gene Ther 2004; 4: 263-276.
16. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
17. Brenner S, Malech HL. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim Biophys Acta 2003; 1640: 1-24.
18. Raper SE et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
19. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 2002; 16: 3-10.
20. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
21. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res 2003; 88: 53-99.
22. Baum C et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9: 5-13.
23. Li Z et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
24. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994; 91: 2567-2571.
25. Garrick D, Fiering S, Martin DIK, Whitelaw E. Repeat-induced gene silencing in mammals. Nat Genet 1998; 18: 56-59.
26. Pannell D et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J 2000; 19: 5884-5894.
27. Doerfler W et al. Integration of foreign DNA and its consequences in mammalian systems. Trends Biotechnol 1997; 15: 297-301.
28. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991; 88: 1330-1334.
29. Hoeben RC et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast lines is associated with methylation and dependent on its chromosomal position. J Virol 1991; 65: 904-912.
30. Dorer DR, Henikoff S. Expansions of transgene repeats cause heterochromatin formation and gene silencing in Drosophila. Cell 1994; 77: 993-1002.
31. Bingham PM. Cosuppression comes to the animals. Cell 1997; 90: 385-387.
32. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
33. Larochelle A et al. Identification of primitive human hematopoietic cells capable of repopulating NODlSCID mouse bone marrow: implications for gene therapy. Nat Med 1996; 2: 1329-1337.
34. Nolta JA, Smogorzecwska EM, Kohn DB. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood 1995; 86: 101-110.
35. Tisdale JF et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished longterm repopulating ability. Blood 1998; 92: 1131-1141.
36. Williams DA. Ex vivo expansion of hematopoietic stem and progenitor cells: robbing Peter to pay Paul? Blood 1993; 81: 3169-3172.
37. Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol 2002; 13: 429-436.
38. Nishikawa M, Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 2002; 25: 275-283.
39. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Therapy 2002; 9: 1647-1652.
40. Brenner MK. Emerging applications of gene transfer in the hematopoietic cancers. J Pediatr Hemat Oncol 1997; 19: 1-6.
41. Kumar VV, Singh RS, Chaudhuri A. Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises. Curr Med Chem 2003; 10: 1297-1306.
42. Clark PR, Hersh EM. Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther 1999; 1: 158-176.
43. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Therapy 1995; 2: 710-722.
44. Smith JG, Walzem RL, German JB. Liposomes as agents of DNA transfer. Biochem Biophys Acta 1993; 1154: 327-340.
45. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta 1994; 1189: 195-203.
46. Friend DS, Papahadjopoulos D, Debs RJ. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim Biophys Acta 1996; 1278: 41-50.
47. Zabner J et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270: 18997-19007.
48. Hawley-Nelson P et al. Lipofectamine reagent: a new, higher efficiency polycationic liposome transfection reagent. Focus 1993; 15: 73-79.
49. Teixeira LA et al. An efficient gene transfer system for hematopoietic cell line using transient and stable vectors. J Biotechnol 2001; 88: 159-165.
50. Ilies MA, Seitz WA, Balaban AT. Cationic lipids in gene delivery: principles, vector design and therapeutic applications. Curr Pharm Des 2002; 8: 2441-2473.
51. Hyde SC et al. Repeat administration of DNAlliposomes to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 2000; 7: 1156-1165.
52. Floch V et al. Cationic phosphonolipids as non viral vectors for DNA transfection in hematopoietic cell lines and CD34+ cells. Blood Cell Mol Dis 1997; 23: 69-87.
53. Harrison GS et al. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. Biotechniques 1995; 19: 816-823.
54. Satoh E et al. Efficient gene transduction by Epstein-Barr virus- based vectors coupled with cationic liposome and HVJ- liposome. Biochem Biophys Res Commun 1997; 238: 795-799.
55. Labat-Moleur F et al. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Therapy 1996; 3: 1010-1017.
56. Boussif O, Zanta MA, Behr JP. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Therapy 1996; 3: 1074-1080.
57. Marit G et al. Increased liposome-mediated gene transfer into hematopoietic cells grown in adhesion to stromal or fibroblast cell line monolayers. Eur J Haematol 2000; 64: 22-31.
58. Keller H et al. Transgene expression, but not gene delivery, is improved by adhesion-assisted lipofection of hematopoietic cells. Gene Therapy 1999; 6: 931-938.
59. Floch V et al. Transgene expression kinetics after transfection with cationic phosphonolipids in hematopoietic non adherent cells. Biochim Biophys Acta 1998; 1371: 53-70.
60. Brunner S et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Therapy 2000; 7: 401-407.
61. Yang NS et al. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990; 87: 9568-9572.
62. Gainer AL et al. Successful biolistic transformation of mouse pancreatic islets while preserving cellular function. Trasplanta- tion 1996; 61: 1567-1571.
63. Huang H, Pannetier C, Hu-Li J, Paul WE. Transient transfection of primary T helper cells by particle-mediated gene transfer. J Immunol Methods 1998; 215: 173-177.
64. Ye ZQ et al. Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery. Hum Gene Ther 1998; 9: 2197-2205.
65. Verma S et al. Gene transfer into human umbilical cord blood- derived CD34+ cells by particle-mediated gene transfer. Gene Therapy 1998; 5: 692-699.
66. Chang DC, Reese TS. Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy. Biophys J 1990; 58: 1-12.
67. Weaver JC. Molecular basis for cell membrane electroporation. Ann NY Acad Sci 1994; 720: 141-152.
68. Klenchin VA et al. Electrically induced DNA uptake by cells is a fast process involving DNA electrophoresis. Biophys J 1991; 60: 804-811.
69. Sukharev SI et al. Electroporation and electrophoretic DNA transfer into cells. The effect of DNA interaction with electropores. Biophys J 1992; 63: 1320-1327.
70. Rols MP et al. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168-171.
71. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-845.
72. Mir LM et al. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 1988; 175: 15-25.
73. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 2004; 6 (Suppl 1): S11-S23.
74. Takahashi M et al. Gene transfer into human leukemia cell lines by electroporation: experience with exponentially decaying and square wave pulse. Leuk Res 1991; 15: 507-513.
75. Pahl HL, Burn TC, Tenen DG. Optimization of transient transfection into human myeloid cell lines using a luciferase reporter gene. Exp Hematol 1991; 19: 1038-1041.
76. Toneguzzo F, Keating A. Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field- mediated DNA transfer. Proc Natl Acad Sci USA 1986; 83:3496-3499.
77. Keating A, Toneguzzo F. Gene transfer by electroporation: a model for gene therapy. Prog Clin Biol Res 1990; 333: 491-498.
78. Wu MH et al. Efficient expression of foreign genes in human CD34+ hematopoietic precursor cells using electroporation. Gene Therapy 2001; 8: 384-390.
79. Wu MH, Smith SL, Dolan ME. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. Stem Cells 2001; 19: 492-499.
80. Wu MH et al. Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporation. Bone Marrow Transplant 2001; 27: 1201-1209.
81. Satoh E et al. Successful transfer of ADA gene in vitro into human peripheral blood CD34+ cells by transfecting EBV-based episomal vectors. FEBS Lett 1998; 441: 39-42.
82. Oliveira DM, Goodell MA. Transient RNA interference in hematopoietic progenitors with functional consequences. Genesis 2003; 36: 203-208.
83. Van Tendeloo VF et al. High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery. Gene Therapy 2000; 7: 1431-1437.
84. Weissinger F et al. Gene transfer in purified human hematopoietic peripheral-blood stem cells by means of electroporation without prestimulation. J Lab Clin Med 2003; 141: 138-149.
85. Takahashi M et al. Efficient introduction of a gene into hematopoietic cells in S-phase by electroporation. Exp Hematol 1991; 19: 343-346.
86. Takahashi M et al. Gene introduction into granulocyte-macrophage progenitor cells by electroporation: the relationship between introduction efficiency and the proportion of cells in S-phase. Leuk Res 1992; 16: 761-767.
87. Yorifuji T, Tsuruta S, Mikawa H. The effect of cell synchronization in the efficiency of stable gene transfer by electroporation. FEBS Lett 1989; 245: 201-203.
88. Papapetrou EP et al. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying a SlMAR element. Gene Therapy advance online publication, 11 August 2005;.
89. Li LH, McCarthy P, Hui SW. High-efficiency electrotransfection of human primary hematopoietic stem cells. FASEB J 2001; 15: 586-588.
90. Gordillo GM. Pathological consequences of unavoidable plasmid contamination with lipopolysaccharide. Transplant Immunol 1999; 7: 83-94.
91. Van Tendeloo VF et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
92. Gehl J et al. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999; 1428: 233-240.
93. Kinosita K, Tsong TY. Voltage-induced pore formation and hemolysis of human erythrocytes. Biochim Biophys Acta 1997; 471: 227-242.
94. Lee RC et al. Surfactant-induced sealing of electropermeabi- lized skeletal muscle membranes in vivo. Proc Natl Acad Sci USA 1992; 89: 4524-4528.
95. Li LH et al. Apoptosis induced by DNA-uptake limits transfection efficiency. Exp Cell Res 1999; 253: 541-550.
96. Hofmann F et al. Electric field pulses can induce apoptosis. J Membr Biol 1999; 169: 103-109.
97. Watanabe M et al. Gene transfection of mouse primordial germ cells in vitro and analysis of their survival and growth control. Exp Cell Res 1997; 230: 76-83.
98. Li LH, Ross P, Hui SW. Improving electrotransfection efficiency by post-pulse centrifugation. Gene Therapy 1999; 6: 364-372.
99. Kinosita K, Tsong TY. Formation and resealing of pores of controlled sizes in human erythrocyte membranes. Nature 1997; 268: 438-441.
100. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998; 9: 319-325.
101. Eppich HM et al. Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants. Nat Biotechnol 2000; 18: 882-887.
102. Kobayashi N, Saeki K, Yuo A. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce cell cycle progression through the synthesis of c-Myc protein by internal ribosome entry site-mediated translation via phosphatidylino- sitol 3-kinase pathway in human factor-dependent leukemic cells. Blood 2003; 102: 3186-3195.
103. Carlile GW, Smith DH, Wiedmann M. Caspase-3 has a nonapoptotic function in erythroid maturation. Blood 2004; 103: 4310-4316.
104. Podar K et al. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem 2004; 279: 21658-21665.
105. Ludtke JJ, Sebestyen MG, Wolff JA. The effect of cell division on the cellular dynamics of microinjected DNA and dextran. Mol Ther 2002; 5: 579-588.
106. Baum C. Transfection. In: Creighton TE (ed). Encyclopedia of Molecular Biology. Wiley and Sons: New York, 1999, pp 2596-2600.
107. Wang Z et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Therapy 2004; 11: 711-721.
108. Milot E, Belmaaza A, Rassart E, Chartrand P. Association of a host DNA structure with retroviral integration sites in chromosomal DNA. Virology 1994; 20: 408-412.
109. Hwang LH, Gilboa E. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J Virol 1984; 50: 417-424.
110. Mielke C, Maass K, Tummler M, Bode J. Anatomy of highly expressing chromosomal sites targeted by retroviral vectors. Biochemistry 1996; 35: 2239-2252.
111. Baer A, Schubeler D, Bode J. Transcriptional properties of genomic transgene integration sites marked by electroporation or retroviral infection. Biochemistry 2000; 39: 7041-7049.
112. Aksentijevich I et al. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum Gene Ther 1996; 7: 1111-1122.
113. Vos J-M. Therapeutic mammalian artificial chromosomes. Curr Opin Mol Ther 1999; 1: 204-205.
114. Lipps HJ, Bode J. Exploiting chromosomal and viral strategies: the design of safe and efficient non-viral gene transfer systems. Curr Opin Mol Ther 2001; 3: 133-141.
115. Lipps HJ et al. Chromosome-based vectors for gene therapy. Gene 2003; 304: 23-33.
116. Van Craenenbroeck K, Vanhoenacker P, Haegeman G. Episomal vectors for gene expression in mammalian cells. Eur J Biochem 2000; 267: 5665-5678.
117. Krysan PJ, Haase SB, Calos MP. Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol 1989; 9: 1026-1033.
118. Kelleher ZT et al. Epstein-Barr-based episomal chromosomes shuttle 100 kb of self-replicating circular human DNA in mouse cells. Nat Biotechnol 1998; 16: 762-768.
119. DuBridge RB et al. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle vector. Mol Cell Biol 1987; 7: 379-387.
120. Legerski R, Peterson C. Expression cloning of a human DNA repair gene involved in xeroderma pigmentosum group C. Nature 1992; 360: 610.
121. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12: 463-466.
122. Cooper MJ et al. Safety-modified episomal vectors for human gene therapy. Proc Natl Acad Sci USA 1997; 94: 6450-6455.
123. Sclimenti CR, Calos MP. Epstein-Barr virus vectors for gene expression and transfer. Curr Opin Biotechnol 1998; 9: 476-479.
124. WadeMartins R et al. Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene. Nat Biotechnol 2000; 18: 1311-1314.
125. Black J, Vos J-M. Establishment of an oriPlEBNA1- based episomal vector transcribing human genomic ß-globin in cultured murine fibroblasts. Gene Therapy 2002; 9: 1447-1454.
126. Chow C-M et al. LCR-mediated, long-term tissue-specific gene expression within replicating episomal plasmid and cosmid vectors. Gene Therapy 2002; 9: 327-336.
127. Mazda O, Satoh E, Yasutomi K, Imanishi J. Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. J Immunol Methods 1997; 204: 143-151.
128. Mazda O et al. A reporter system using a flow cytometer to detect promoterlenhancer activity in lymphoid cell lines. J Immunol Methods 1994; 169: 53-61.
129. Mucke S et al. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Therapy 1997; 4: 82-92.
130. Stoll SM, Calos MP. Extrachromosomal plasmid vectors for gene therapy. Curr Opin Mol Ther 2002; 4: 299-305.
131. Heller RA et al. Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries. J Biol Chem 1990; 265: 5708-5717.
132. Sun TQ, Fernstermacher DA, Vos JM. Human artificial episomal chromosomes for cloning large DNA fragments in human cells. Nat Genet 1994; 8: 33-41.
133. Simpson K, McGuigan A, Huxley C. Stable episomal maintenance of yeast artificial chromosomes in human cells. Mol Cell Biol 1996; 16: 5117-5126.
134. Belt PB et al. Efficient cDNA cloning by direct phenotypic correction of a mutant human cell line (HPRT—) using an Epstein-Barr virus-derived cDNA expression vector. Nucleic Acids Res 1991; 19: 4861-4866.
135. Mazda O. Improvement of nonviral gene therapy by Epstein- Barr virus (EBV)-based plasmid vectors. Curr Gene Ther 2002; 2: 1-14.
136. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; 65: 483-488.
137. Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987; 61: 1590-1594.
138. Drinkwater NR, Klinedinst DK. Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency. Proc Natl Acad Sci USA 1986; 83: 3402-3406.
139. Vidal M et al. Differences in human cell lines to support stable replication of Epstein-Barr virus-based vectors. Biochim Biophys Acta 1990; 1048: 171-177.
140. Krysan PJ, Calos MP. Epstein-Barr virus-based vectors that replicate in rodent cells. Gene 1993; 136: 137-143.
141. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Therapy 1998; 5: 1031-1037.
142. Kirchmaier AL, Sugden B. Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 1995; 69: 1280-1283.
143. Middleton T, Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 1994; 68: 4067-4071.
144. Rice PW, Cole CN. Efficient transcriptional activation of many simple modular promoters by simian virus 40 large T-antigen. J Virol 1993; 67: 6689-6697.
145. Slinskey A, Barnes D, Pipas JM. Simian virus 40 large T-antigen J domain and Rb-binding motif are sufficient to block apoptosis induced by growth factor withdrawal in a neural stem cell line. J Virol 1999; 73: 6791-6799.
146. Mukherjee S et al. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1- expressing mouse cells. J Exp Med 1998; 187: 445-450.
147. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
148. Snudden DK et al. EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins. EMBO J 1994; 13: 4840-4847.
149. Lei DC et al. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells. Gene Therapy 1996; 3: 427-436.
150. Banerjee S, Livanos E, Vos J-M. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nat Med 1995; 1: 1303-1308.
151. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
152. Grimes BR, Warburton PE, Farr CJ. Chromosome engineering: prospects for gene therapy. Gene Therapy 2002; 9: 713-718.
153. Saffery R, Choo KH. Strategies for engineering human chromosomes with therapeutic potential. J Gene Med 2002; 4: 5-13.
154. Harrington JJ et al. Formation of de novo centromeres and construction of first generation human artificial microchromosomes. Nat Genet 1997; 15: 345-355.
155. Grimes BR et al. Stable expression from a mammalian artificial chromosome. EMBO Rep 2001; 2: 910-914.
156. Meija JE et al. Functional complementation of genetic deficiency with human artificial chromosomes. Am J Hum Genet 2001; 69: 315-326.
157. Auriche C et al. Functional human CFTR produced by a stable minichromosome. EMBO Rep 2002; 3: 826-828.
158. Vanderbyl S et al. Transgene expression after stable transfer of a mammalian artificial chromosome into human hematopoietic cells. Blood 2004; 104:(abstract 498).
159. Piechaczek C et al. A vector based on the SV40 origin of replication and chromosomal SlMARs replicates episomally in CHO cells. Nucleic Acids Res 1999; 27: 426-428.
160. Bode J et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 1992; 255: 195-197.
161. Schaarschmidt D et al. An episomal mammalian replicon: sequence-independent binding of the origin recognition complex. EMBO J 2004; 23: 191-201.
162. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ. Expression of a transgene encoded on a non-viral episomal vector is not subject S129 to epigenetic silencing by cytokine methylation. Mol Biol Rep 2004; 31: 85-90.
163. Baiker A et al. Mitotic stability of an episomal vector containing a human scaffoldlmatrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000; 2: 182-184.
164. Jenke BH et al. An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo. EMBO Rep 2002; 3: 349-354.
165. Corrias MV et al. Growth factors increase retroviral transduction but decrease clonogenic potential of umbilical cord blood CD34+ cells. Haematologica 1998; 83: 580-586.
166. Lechardeur D et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Therapy 1999; 6: 482-497.
167. Greber UF et al. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J 1997; 16: 5998-6007.
168. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
169. Zanta M-A, Belguise-Valladier P, Behr J-P. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 1999; 96: 91-96.
170. Remy JS et al. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses. Proc Natl Acad Sci USA 1995; 92: 1744-1748.
171. Fominaya J, Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J Biol Chem 1996; 271: 10560-10568.
172. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93: 11341-11348.
173. Jin CH et al. Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. Gene Therapy 2003; 10: 272-277.
174. Montini E et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 2002; 6: 759-769.
175. Olivares EC et al. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol 2002; 20: 1124-1128.
176. Ortiz-Urda S et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002; 8: 1166-1170.
177. Herweijer H et al. Time course of gene expression after plasmid DNA gene transfer to the liver. J Gene Med 2001; 3: 280-291.
178. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Therapy 1996; 3: 802-810.
179. Yew NS et al. Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum Gene Ther 1997; 8: 575-584.
180. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
181. Qin L et al. Promoter attenuation in gene therapy: interferongamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
182. Paillard F. CpG: the double-edged sword. Hum Gene Ther 1999; 10: 2089-2090.
183. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Therapy 2004; 11: 856-864.
184. Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999; 10: 2153-2161.
185. Krieg AM et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
186. Krieg AM et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998; 95: 12631-12636.
187. Gill DR et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Therapy 2001; 8: 1539-1546.
188. Alino SF, Crespo A, Dasi F. Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA. Gene Therapy 2003; 10: 1672-1679.
189. Hofman CR et al. Efficient in vivo gene transfer by PCR amplified fragment with reduced inflammatory activity. Gene Therapy 2001; 8: 71-74.
190. Darquet AM et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Therapy 1997; 4:1341-1349.
191. Ebert O et al. Lymphocyte apoptosis induction by gene transfer techniques. Gene Therapy 1997; 4: 296-302.
192. Yew NS et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999; 10: 223-234.
193. Schleef M, Schmidt T. Animal-free production of ccc-super- coiled plasmids for research and clinical applications. J Gene Med 2004; 6: S45-S53.